{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:56:28Z","timestamp":1769072188277,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11060-023-04467-4","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:02:40Z","timestamp":1695808960000},"page":"693-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy"],"prefix":"10.1007","volume":"164","author":[{"given":"Archis R.","family":"Bhandarkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaan","family":"Bhandarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusica","family":"Babovic-Vuksanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian F.","family":"Parney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"17","key":"4467_CR1","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41388-022-02290-1","volume":"41","author":"BN Somatilaka","year":"2022","unstructured":"Somatilaka BN, Sadek A, McKay RM, Le LQ (2022) Malignant peripheral nerve sheath tumor: models, Biology, and translation. Oncogene 41(17):2405","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"4467_CR2","first-page":"i50","volume":"2","author":"A Pemov","year":"2020","unstructured":"Pemov A, Li H, Presley W, Wallace MR, Miller DT (2020) Genetics of human malignant peripheral nerve sheath tumors. Neurooncol Adv 2(Suppl 1):i50\u2013i61","journal-title":"Neurooncol Adv"},{"key":"4467_CR3","doi-asserted-by":"publisher","unstructured":"Mohamad T, Plante C, Brosseau JP (2021) Toward understanding the Mechanisms of malignant peripheral nerve sheath Tumor Development. Int J Mol Sci 22(16). https:\/\/doi.org\/10.3390\/ijms22168620","DOI":"10.3390\/ijms22168620"},{"issue":"11","key":"4467_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","volume":"24","author":"PMK de Blank","year":"2022","unstructured":"de Blank PMK, Gross AM, Akshintala S et al (2022) MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. Neuro Oncol 24(11):1845\u20131856","journal-title":"Neuro Oncol"},{"key":"4467_CR5","doi-asserted-by":"publisher","unstructured":"Guo MZ, Balaji A, Murray JC et al (2023) Infectious complications in patients with non-small cell lung Cancer treated with Immune Checkpoint inhibitors. Clin Lung Cancer. Published Online June 20. https:\/\/doi.org\/10.1016\/j.cllc.2023.06.011","DOI":"10.1016\/j.cllc.2023.06.011"},{"key":"4467_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fnmol.2019.00111","volume":"12","author":"L Larrib\u00e8re","year":"2019","unstructured":"Larrib\u00e8re L, Utikal J (2019) Stem cell-derived models of neural crest are essential to Understand Melanoma Progression and Therapy Resistance. Front Mol Neurosci 12:111","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"4467_CR7","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550\u20131558","journal-title":"Nat Med"},{"issue":"10","key":"4467_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander N, Zhang G, Lee JS et al (2018) Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med 24(10):1545\u20131549","journal-title":"Nat Med"},{"issue":"1","key":"4467_CR9","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1038\/s41467-023-38432-6","volume":"14","author":"S Suppiah","year":"2023","unstructured":"Suppiah S, Mansouri S, Mamatjan Y et al (2023) Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. Nat Commun 14(1):2696","journal-title":"Nat Commun"},{"issue":"44","key":"4467_CR10","doi-asserted-by":"publisher","first-page":"eabo5442","DOI":"10.1126\/sciadv.abo5442","volume":"8","author":"LMN Wu","year":"2022","unstructured":"Wu LMN, Zhang F, Rao R et al (2022) Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv 8(44):eabo5442","journal-title":"Sci Adv"},{"key":"4467_CR11","doi-asserted-by":"publisher","unstructured":"Yan J, Chen Y, Patel AJ et al (2022) Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses. J Clin Invest 132(17). https:\/\/doi.org\/10.1172\/JCI153437","DOI":"10.1172\/JCI153437"},{"issue":"3","key":"4467_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00401-021-02341-z","volume":"142","author":"V Kochat","year":"2021","unstructured":"Kochat V, Raman AT, Landers SM et al (2021) Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol 142(3):565\u2013590","journal-title":"Acta Neuropathol"},{"issue":"12","key":"4467_CR13","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-19-2706","volume":"26","author":"JL Kohlmeyer","year":"2020","unstructured":"Kohlmeyer JL, Kaemmer CA, Pulliam C et al (2020) RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes Tumor cells to CDK4\/6 inhibitors. Clin Cancer Res 26(12):2997\u20133011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4467_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo W, Zaretsky JM, Sun L et al (2017) Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell 168(3):542","journal-title":"Cell"},{"issue":"6257","key":"4467_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207\u2013211","journal-title":"Science"},{"issue":"39","key":"4467_CR16","doi-asserted-by":"publisher","first-page":"64300","DOI":"10.18632\/oncotarget.11734","volume":"7","author":"E Shurell","year":"2016","unstructured":"Shurell E, Singh AS, Crompton JG et al (2016) Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8 + tumor infiltrating lymphocytes. Oncotarget 7(39):64300\u201364308","journal-title":"Oncotarget"},{"issue":"4","key":"4467_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CJI.0000000000000410","volume":"45","author":"K Larson","year":"2022","unstructured":"Larson K, Russ A, Arif-Tiwari H et al (2022) Pembrolizumab achieves a complete response in an NF-1 mutated, PD-L1 positive malignant peripheral nerve sheath tumor: a Case Report and Review of the Benchmarks. J Immunother 45(4):222\u2013226","journal-title":"J Immunother"},{"issue":"9","key":"4467_CR18","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1158\/2326-6066.CIR-19-0072","volume":"7","author":"LE Davis","year":"2019","unstructured":"Davis LE, Nicholls LA, Babiker HM, Liau J, Mahadevan D (2019) PD-1 inhibition achieves a complete metabolic response in a patient with malignant peripheral nerve sheath tumor. Cancer Immunol Res 7(9):1396\u20131400","journal-title":"Cancer Immunol Res"},{"key":"4467_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00375","volume":"3","author":"BC \u00d6zdemir","year":"2019","unstructured":"\u00d6zdemir BC, Bohanes P, Bisig B et al (2019) Deep response to Anti-PD-1 therapy of metastatic neurofibromatosis type 1-Associated Malignant Peripheral nerve sheath tumor with amplification. JCO Precis Oncol 3:1\u20136","journal-title":"JCO Precis Oncol"},{"key":"4467_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.critrevonc.2019.04.007","volume":"138","author":"E Martin","year":"2019","unstructured":"Martin E, Lamba N, Flucke UE et al (2019) Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): a systematic review from bench to bedside. Crit Rev Oncol Hematol 138:223\u2013232","journal-title":"Crit Rev Oncol Hematol"},{"key":"4467_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejca.2021.04.034","volume":"152","author":"M Saerens","year":"2021","unstructured":"Saerens M, Brusselaers N, Rottey S, Decruyenaere A, Creytens D, Lapeire L (2021) Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: a systematic review and meta-analysis. Eur J Cancer 152:165\u2013182","journal-title":"Eur J Cancer"},{"issue":"7","key":"4467_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/cam4.732","volume":"5","author":"S Yun","year":"2016","unstructured":"Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I (2016) Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 5(7):1481\u20131491","journal-title":"Cancer Med"},{"issue":"7","key":"4467_CR23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","volume":"6","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Ghidini M, Ghidini A, Tomasello G (2020) Outcomes following Immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and Meta-analysis. JAMA Oncol 6(7):1068\u20131071","journal-title":"JAMA Oncol"},{"issue":"4","key":"4467_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL et al (2019) An evolutionarily conserved function of polycomb silences the MHC Class I Antigen Presentation Pathway and enables Immune Evasion in Cancer. Cancer Cell 36(4):385\u2013401e8","journal-title":"Cancer Cell"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04467-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04467-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T21:22:33Z","timestamp":1703280153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04467-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04467-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"27 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}